tbuckley/cabot-search huggingface dataset:
HER2+ gastric cancer patient demographics and implications for clinical trial enrollment.
Authors: Paulina Zelenay McAtee, Ashley Erickson Simmons, Marie-Edith Anne Bonneterre, Dirk J. Reitsma, Jaikrishna Balkissoon, Peter J. Wyld, Angelena Moseley, Austin James Combest
Journal: Journal of Clinical Oncology (2014)

e12526 Background: HER2 targeting in gastric cancer (GC) is a relatively new approach. The ToGA trial demonstrated the importance of HER2 over-expression in GC. Unlike breast cancer, little information exists on patient demographics, especially in HER2+ GC. With a number of drugs in the pipeline focusing on the HER2 target, we aim to evaluate potential deterrents to enrollment in clinical trials. The objective of this epidemiological evaluation is to provide an overview of patient demographics, frequency of HER2 testing, and incidence of HER2 positivity in GC. This information will give a comprehensive picture of the GC population, promoting future trial design and enhancing enrollment. Methods: Data were collected using the Ipsos database, a commercial system containing de-identified patient information entered by oncologists. The data includes demographic information as well as HER2+ overexpression screening frequencies for GC. Results: See Table. Conclusions: Our data show that 27% of patients with mGC are not-tested for HER2 status and of those tested up to 34% of results are inconclusive. Of the HER2+ mGC patients, 84% received first-line trastuzumab or lapatinib. Several open second- line trials of promising targeted agents (including TDM1, afatinib, AVX-901 and LJM-716) require prior HER2-targeted treatment and progression. This data indicates that approximately 43% of patients are either not tested or do not receive HER2 targeted therapy which limits participation in second-line trials requiring prior HER2 targeted therapy. Other demographic data including age >75 (13%) also limit the eligible population. Increased HER2 testing and consensus in treatment guidelines is needed to improve identification of patients with HER2 positive tumors and their eligibility for clinical trials. HER2+ GC DATA Oct '12-Sept '13. Percentage Total (N=1,453) 100 Age Range <45 <3 45-54 31 55-64 33 65-74 21 75-84 13 Mean age 59.94, SD 11.84 Gender Male 65 Female 35 Ethnicity White 51 Asian 8 Black 34 Hispanic 6 Other 2 Smoking status Smoker/quit 62 Non-smoker 38 Stage IV HER2 testing Tested 73 Not-tested 27 HER2 status (IHC/FISH scores) Historical HER2+ incidence 17-20 Positive 15 Received 1L HER2-targeted treatment 84 Negative 51 Inconclusive/awaiting results 34
A Pooled Overall Survival (OS) Analysis of 5-Year Data from the COMFORT-I and COMFORT-II Trials of Ruxolitinib for the Treatment of Myelofibrosis (MF)
Authors: Srdan Verstovsek, Vikas Gupta, Jason R. Gotlib, Ruben A. Mesa, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Francisco Cervantes, William Sun, Jessy Gao, Touchuan Dong, Ahmad Naim, Prashanth Gopalakrishna, Claire N. Harrison
Journal: Blood (2016)
Abstract P4-12-04: Breast cancer subtype, age and lymph node status as predictors of local recurrence following breast-conserving therapy
Authors: LZ Braunstein, AG Taghian, A Niemierko, L Salama, A Capuco, JS Wong, RS Punglia, JR Bellon, SM MacDonald, JR Harris
Journal: Cancer Research (2017)

Abstract Purpose/Objectives: Advances in breast-conserving therapy (BCT) have yielded local control rates comparable or superior to those of mastectomy. Here, we sought to identify risk factors associated with isolated local recurrence (LR) following BCT. Materials/Methods: This study included a multi-institutional cohort of 2,233 consecutive breast cancer patients who underwent BCT between 1998 and 2007. Patient characteristics and disease parameters were stratified by age, subtype and nodal status. Biologic subtype was approximated by receptor status and tumor grade. No patients received HER2/neu-directed therapy. The association of clinicopathologic features with LR was evaluated using Cox proportional hazards regression models. Results: At a median follow-up of 106 months, 69 LR events (3.1%) were observed. Among the overall cohort, 10-year freedom from LR was 95.9%. On univariate Cox regression analysis, risk factors associated with LR included subtype other than luminal A (hazard ratio [HR] for luminal B = 3.01, HER2 = 6.29, triple negative [TNBC] = 4.72; p&amp;lt;0.001 for each), younger age (HR of oldest versus youngest quartile = 0.43; p=0.005), regional lymph node involvement (HR for 4-9 involved nodes = 3.04; &amp;gt;9 nodes = 5.82; p&amp;lt;0.01 for each), positive resection margins (HR = 2.43; p=0.005), and high-grade disease (HR = 5.37; p &amp;lt;0.001). Presence of LVI (HR = 1.56; p=0.06) or 1-3 involved nodes (HR = 1.55; p=0.07) approached significance. Multivariate Cox regression demonstrated an association with LR among those with non-luminal A subtypes (HR for luminal B = 2.64, HER2 = 5.42, TNBC = 4.32; p&amp;lt;0.001 for each), younger age (HR for age &amp;gt;50 = 0.56; p=0.01), and any nodal disease (HR=1.06 per involved node; p&amp;lt;0.004). Conclusions: BCT yields favorable outcomes for the large majority of patients, although increased LR was observed among those with non-luminal A subtypes, younger age, and increasing lymph node involvement. Risk factors for LR following BCT appear to be converging with those following mastectomy in the current era. Citation Format: Braunstein LZ, Taghian AG, Niemierko A, Salama L, Capuco A, Wong JS, Punglia RS, Bellon JR, MacDonald SM, Harris JR. Breast cancer subtype, age and lymph node status as predictors of local recurrence following breast-conserving therapy [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-12-04.
Posttraumatic Stress Disorder in a Young Adult Military Veteran
Authors: David A. Ross, Michael J. Travis, Melissa R. Arbuckle
Journal: JAMA Psychiatry (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Abstract ES8-2: ES8-2 Energy balance: The new adjuvant therapy?
Authors: ML Irwin
Journal: Cancer Research (2017)

Abstract Obesity affects the risk of breast cancer development and the risk of recurrence and death from breast cancer. Furthermore, weight gain after diagnosis of breast cancer (independent of BMI at diagnosis) is associated with higher all-cause mortality rates compared with maintaining body weight. The American Cancer Society (ACS) recommends cancer survivors achieve and maintain a healthy weight, follow a dietary pattern high in vegetables, fruits, and whole grains, engage in 150 minutes per week of aerobic exercise plus two strength training sessions per week, and avoid physical inactivity. Despite these recommendations, over 65% of breast cancer survivors are overweight or obese, and fewer than 30% engage in recommended levels of physical activity. Recently, the American Society of Clinical Oncology (ASCO) published a position statement on obesity and cancer with a multipronged initiative to reduce the impact of obesity on cancer, with one of the initiatives focused on determining best methods to help cancer survivors make effective changes in lifestyle behaviors. The impact of weight loss and exercise trials on breast cancer outcomes, as well as future research opportunities and the role of clinical and community-based weight management programs, will be discussed. Citation Format: Irwin ML. ES8-2 Energy balance: The new adjuvant therapy? [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr ES8-2.
Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment
Authors: Sobeyda B. Gomez-Chou, Agnieszka Katarzyna Swidnicka-Siergiejko, Niharika Badi, Myrriah Chavez-Tomar, Gregory B. Lesinski, Tanios Bekaii-Saab, Matthew R. Farren, Thomas A. Mace, Carl Schmidt, Yan Liu, Defeng Deng, Rosa F. Hwang, Liran Zhou, Todd Moore, Deyali Chatterjee, Huamin Wang, Xiaohong Leng, Ralph B. Arlinghaus, Craig D. Logsdon, Zobeida Cruz-Monserrate
Journal: Cancer Research (2017)

Lipocalin-2 (LCN2) promotes malignant development in many cancer types. LCN2 is upregulated in patients with pancreatic ductal adenocarcinoma (PDAC) and in obese individuals, but whether it contributes to PDAC development is unclear. In this study, we investigated the effects of Lcn2 depletion on diet-induced obesity, inflammation, and PDAC development. Mice with acinar cell-specific expression of KrasG12D were crossed with Lcn2-depleted animals and fed isocaloric diets with varying amounts of fat content. Pancreas were collected and analyzed for inflammation, pancreatic intraepithelial neoplasia (PanIN), and PDAC. We also used a syngeneic orthotopic PDAC mouse model to study tumor growth in the presence or absence of Lcn2 expression. In addition, to understand the mechanistic role of how LCN2 could be mediating PDAC, we studied LCN2 and its specific receptor solute carrier family 22 member 17 (SLC22A17) in human pancreatic cancer stellate cells (PSC), key mediators of the PDAC stroma. Depletion of Lcn2 diminished extracellular matrix deposition, immune cell infiltration, PanIN formation, and tumor growth. Notably, it also increased survival in both obesity-driven and syngeneic orthotopic PDAC mouse models. LCN2 modulated the secretion of proinflammatory cytokines in PSC of the PDAC tumor microenvironment, whereas downregulation of LCN2-specific receptor SLC22A17 blocked these effects. Our results reveal how LCN2 acts in the tumor microenvironment links obesity, inflammation, and PDAC development. Cancer Res; 77(10); 2647-60. ©2017 AACR.
Identification of Phenotype Profile Related to the Extramedullary Involvement in Multiple Myeloma Relapse
Authors: Lucie Rihova, Pavla Vsianska, Renata Bezdekova, Zdenek Adam, Miroslav Penka, Tomas Jelinek, Sabina Sevcikova, Ludek Pour, Roman Hájek
Journal: Blood (2016)
Impact of Computed Tomography Perfusion Imaging on the Response to Tenecteplase in Ischemic Stroke
Authors: Andrew Bivard, Xuya Huang, Patrick McElduff, Christopher R. Levi, Bruce C.V. Campbell, Bharath Kumar Cheripelli, Dheeraj Kalladka, Fiona Catherine Moreton, Ian Ford, Christopher F. Bladin, Stephen M. Davis, Geoffrey A. Donnan, Keith W. Muir, Mark W. Parsons
Journal: Circulation (2016)

Background: We pooled 2 clinical trials of tenecteplase compared with alteplase for the treatment of acute ischemic stroke, 1 that demonstrated superiority of tenecteplase and the other that showed no difference between the treatments in patient clinical outcomes. We tested the hypotheses that reperfusion therapy with tenecteplase would be superior to alteplase in improving functional outcomes in the group of patients with target mismatch as identified with advanced imaging. Methods: We investigated whether tenecteplase-treated patients had a different 24-hour reduction in the National Institutes of Health Stroke Scale and a favorable odds ratio of a modified Rankin scale score of 0 to 1 versus 2 to 6 compared with alteplase-treated patients using linear regression to generate odds ratios. Imaging outcomes included rates of vessel recanalization and infarct growth at 24 hours and occurrence of large parenchymal hematoma. Baseline computed tomography perfusion was analyzed to assess whether patients met the target mismatch criteria (absolute mismatch volume &gt;15 mL, mismatch ratio &gt;1.8, baseline ischemic core &lt;70 mL, and volume of severely hypoperfused tissue &lt;100 mL). Patients meeting target mismatch criteria were analyzed as a subgroup to identify whether they had different treatment responses from the pooled group. Results: Of 146 pooled patients, 71 received alteplase and 75 received tenecteplase. Tenecteplase-treated patients had greater early clinical improvement (median National Institutes of Health Stroke Scale score change: tenecteplase, 7; alteplase, 2; P =0.018) and less parenchymal hematoma (2 of 75 versus 10 of 71; P =0.02). The pooled group did not show improved patient outcomes when treated with tenecteplase (modified Rankin scale score 0–1: odds ratio, 1.77; 95% confidence interval, 0.89–3.51; P =0.102) compared with alteplase therapy. However, in patients with target mismatch (33 tenecteplase, 35 alteplase), treatment with tenecteplase was associated with greater early clinical improvement (median National Institutes of Health Stroke Scale score change: tenecteplase, 6; alteplase, 1; P &lt;0.001) and better late independent recovery (modified Rankin scale score 0–1: odds ratio, 2.33; 95% confidence interval, 1.13–5.94; P =0.032) than those treated with alteplase. Conclusions: Tenecteplase may offer an improved efficacy and safety profile compared with alteplase, benefits possibly exaggerated in patients with baseline computed tomography perfusion–defined target mismatch. Clinical Trial Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01472926. URL: https://www.anzctr.org.au . Unique identifier: ACTRN12608000466347.
Toward Hydrogen Sulfide Based Therapeutics: Critical Drug Delivery and Developability Issues
Authors: Yueqin Zheng, Bingchen Yu, Ladie Kimberly De La Cruz, Manjusha Roy Choudhury, Abiodun Anifowose, Binghe Wang
Journal: Medicinal Research Reviews (2017)

Abstract Hydrogen sulfide (H 2 S), together with nitric oxide (NO) and carbon monoxide (CO), belongs to the gasotransmitter family and plays important roles in mammals as a signaling molecule. Many studies have also shown the various therapeutic effects of H 2 S, which include protection against myocardial ischemia injury, cytoprotection against oxidative stress, mediation of neurotransmission, inhibition of insulin signaling, regulation of inflammation, inhibition of the hypoxia‐inducible pathway, and dilation of blood vessels. One major challenge in the development of H 2 S‐based therapeutics is its delivery. In this manuscript, we assess the various drug delivery strategies in the context of being used research tools and eventual developability as therapeutic agents.
Tribunal is criticised for spending 57 days hearing a case
Authors: Clare Dyer
Journal: BMJ (2017)

A High Court judge has criticised a medical practitioners tribunal that spent 57 days hearing a case against a consultant gynaecologist before deciding to suspend him from practice for three months.

The hearing into Olofunso Oyesanya’s fitness to practise started in March 2015 and finished in September 2016 after repeatedly running out of time and having to reconvene six times.

Oyesanya, who qualified in Nigeria, was charged with a catalogue of failings, but only three of the allegations were upheld. He is appealing to the High Court against the tribunal’s findings.

Allowing him an adjournment to organise legal representation for the appeal, Mr Justice Holman said that the gynaecologist had “a good and well arguable case.” He added, “Quite frankly, and with all due respect to the tribunal, this case must have got completely …
Phase I Trial of Vorinostat Combined with Cytarabine and Etoposide in Patients (pts) with Advanced Acute Leukemia and High-Risk Myelodysplastic Syndromes
Authors: Ivana Gojo, Ming T. Tan, Ken Shiozawa, Takeo Nakanishi, Angelika M Burger, Colette L Burgess, Merrill J Egorin, Maria R. Baer, Michael L Tidwell, Rakesh Srivastava, France Carrier, Angela Scardina, Igor Espinoza-Delgado, Douglas D. Ross
Journal: Blood (2008)
Abstract P4-02-09: Non-invasive and low-cost technique for early detection of clinically relevant breast lesions using a handheld point-of-care medical device (iBreastExam): Prospective three-arm triple-blinded comparative study for breast cancer screening in low resource setting countries
Authors: SP Somashekhar, KR Ashwin
Journal: Cancer Research (2017)

Abstract This abstract was not presented at the symposium.
Fatal anaphylaxis in France: Analysis of national anaphylaxis data, 1979-2011
Authors: Guillaume Pouessel, Claire Claverie, Julien Labreuche, Aimée Dorkenoo, Jean-Marie Renaudin, Mireille Eb, Stéphanie Lejeune, Antoine Deschildre, Stéphane Leteurtre
Journal: Journal of Allergy and Clinical Immunology (2017)
White Paper AGA: The Impact of Mental and Psychosocial Factors on the Care of Patients With Inflammatory Bowel Disease
Authors: Eva M. Szigethy, John I. Allen, Marci Reiss, Wendy Cohen, Lilani P. Perera, Lili Brillstein, Raymond K. Cross, David A. Schwartz, Lawrence R. Kosinski, Joshua B. Colton, Elizabeth LaRusso, Ashish Atreja, Miguel D. Regueiro
Journal: Clinical Gastroenterology and Hepatology (2017)
Rituximab and dose-adjusted EPOCH (R-EPOCH) for treatment of aggressive B-cell non-Hodgkin lymphomas: A developing country perspective.
Authors: Hasmukh Jain, Tanuja Shet, Epari Sridhar, Hari Menon, Uma Bhaskar Dangi, Bhausaheb Pandurang Bagal, Sumeet Gujral, Siddharth Laskar, Venkatesh Rangarajan, Manju Sengar
Journal: Journal of Clinical Oncology (2013)

e19503 Background: Biological heterogeneity of diffuse large B-cell lymphomas (DLBL) is reflected in variable outcomes with R-CHOP. Clinicopathological features like high IPI, underlying acquired immunodeficiency, non-germinal center phenotype, primary mediastinal B-cell histology and Bcl-2 positivity correlate with adverse biology. Effect of adverse biological attributes is also reflected in outcomes B-cell lymphoma intermediate between diffuse large cell B-cell and Burkitt’s lymphomas (BCLU) and Burkitt’s lymphoma in elderly and HIV-positive individuals with low CD4 counts. Given the promising efficacy of R- EPOCH in poor-risk DLBL we used it in therapy of aggressive B-cell NHL. Methods: From May 2010 to December 2012 patients with de-novo aggressive B-cell lymphomas with adverse clinicopathological features (DLBL with multiple extranodal sites, high IPI, primary mediastinal B-cell lymphoma, BCLU, Burkitt’s lymphoma in elderly or in HIV-positive individuals) were treated with R-EPOCH. Demography,stage, bulk of disease, IPI, CD4 counts, grade 3/4 toxicities and death were recorded. Responses were evaluated at mid and end of therapy. Overall and progression-free survivals were calculated. Immunohistochemistry was used to classify the germinal center and non-germinal center phenotype. Results: 33 patients (males-21, female-12) were treated with median of 6 cycles (range 3-6) of R-EPOCH. Histologicalsubtypes distribution was- DLBL-16, BL-8, BCLU-5, and PMBL-4. Sixty percent of DLBL were non-germinal center type and bcl-2 positive. Median age was 33 years (range 15-73 years). More than 2/3 of patients had stage 3/4 bulky disease with high IPI. Twelve patients were HIV positive with median CD4 count of 173/µL (range 43-359/µL). Complete responses were seen in 66.7% at interim evaluation and in 90% at the end of therapy. At a median follow up of 8 months, 1- year overall survival and progression- free survival were 72.5% and 90% respectively. Two patients died due to therapyand grade 3/4 toxicities were seen in 10% patients. Conclusions: R-EPOCH regimen is efficacious in patients with poor-risk aggressive B-cell NHL however longer follow-up is needed.
Moderate Intensive Chemotherapy Including CNS-Prophylaxis with Liposomal Cytarabine Is Feasible and effective in Older Patients with Ph-Negative Acute Lymphoblastic Leukemia (ALL): Results of a Prospective Trial From the German Multicenter Study Group for Adult ALL (GMALL)
Authors: Nicola Goekbuget, Joachim Beck, Monika Brueggemann, Thomas Burmeister, Eike C. Buss, Norbert Frickhofen, Andreas Huettmann, Anke Morgner, Albrecht Reichle, Ingo Schmidt-Wolf, Stefan Schwartz, Hubert Serve, Bernd M Spriewald, Michael Starck, Matthias Stelljes, Andreas Viardot, Knut Wendelin, Dieter Hoelzer
Journal: Blood (2012)
Comparison of the Myleloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Across Nine Linguistic Translations Among an International Sample of 1,851 Myeloproliferative Neoplasm (MPN) Patients.
Authors: Amylou Constance Dueck, Robyn M. Emanuel, Holly Lynn Geyer, Jean-Jacques Kiladjian, Stephanie Slot, Sonja Zweegman, Peter te Boekhorst, Suzan Commandeur, Harry C Schouten, Federico Sackmann, Ana Kerguelen Fuentes, Dolores Hernandez, Heike L. Pahl, Martin Griesshammer, Frank Stegelmann, Konstanze Doehner, Thomas Lehmann, Karin Bonatz, Andreas Reiter, Françoise Boyer, Gabriel Etienne, Jean-Christophe Ianotto, Dana Ranta, Lydia Roy, Jean-Yves Cahn, Claire N Harrison, Deepti H Radia, Pablo J. Muxi, Norman I Maldonado, Carlos Besses, Francisco Cervantes, Peter Johansson, Tiziano Barbui, Giovanni Barosi, Alessandro M. Vannucchi, Francesco Passamonti, Bjorn Andreasson, Maria L Ferarri, Alessandro Rambaldi, Jan Samuelsson, Gunnar Birgegard, Ayalew Tefferi, Zhijian Xiao, Zefeng Xu, Yue Zhang, Xiujuan Sun, Junqing Xu, Peihong Zhang, Robert Peter Gale, Ruben A. Mesa
Journal: Blood (2012)
A United Kingdom Population-Based Study of Survival in Patients Aged 19 to 60 with Acute Myeloid Leukaemia in the Era of Molecular Genetics
Authors: McGregor K Andrew, Deborah Moulton, Nick Bown, Gavin Cuthbert, Sue Matthew, Philip Mounter, Raymond Kai Bong Dang, Gail Jones
Journal: Blood (2014)
XVI. Clinical Science Gets Enthroned
Authors: Lester S. King
Journal: JAMA (1983)

In the 1890s the laboratory was becoming more and more important for clinical medicine. Although, as we have seen, improved diagnostic tests were making the work of the clinician easier, the improved diagnosis took place for the most part within the old conceptual framework. Yet the new methods, especially in bacteriology and chemistry, were slowly permitting investigators to attack more general problems and to expand the basic concepts. Whereas precise methods, applied to diagnosis, improved the<i>art</i>of medicine, the same methods, when they enlarged the conceptual aspects, entered the realm of science. New techniques, by themselves, no matter how complex, are only tools. We must ask, To what goal are the tools applied? Primarily toward diagnosis? Or primarily toward expansion of knowledge? Osler, in his brief address in 1895,<sup>1</sup>wanted internal medicine to be a specialty that would require long preparation, not only on the wards but in
High Frequency of Point Mutations of BCR/ABL Gene in CML Patients Resistant to Imatinib Therapy - Report of a Novel Mutation.
Authors: Edson Ichihara, Fernando F. Costa, Natasha Busoli, Dulcineia M. Albuquerque, Irene Lorand-Metze, Sara T.O. Saad, Carmino A. De Souza, Afonso C. Vigorito, Katia B.B. Pagnano
Journal: Blood (2004)